Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AC Immune S.A. (NQ: ACIU )

2.375 -0.005 (-0.21%)
Streaming Delayed Price Updated: 12:23 PM EDT, Apr 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 82,143
Open 2.400
Bid (Size) 2.350 (2)
Ask (Size) 2.400 (1)
Prev. Close 2.380
Today's Range 2.350 - 2.470
52wk Range 1.780 - 5.140
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ACIU Stock Earnings: AC Immune Beats EPS, Beats Revenue for Q4 2023
ACIU stock results show that AC Immune beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update
From AC Immune SA
Via GlobeNewswire

Performance

YTD
-49.36%
-49.36%
1 Month
-18.10%
-18.10%
3 Month
-42.07%
-42.07%
6 Month
-15.18%
-15.18%
1 Year
+13.64%
+13.64%

More News

Read More
AC Immune Announces Upcoming Presentations at AD/PD™ 2024
From AC Immune SA
Via GlobeNewswire
AC Immune to Regain Global Rights to Crenezumab and Semorinemab
From AC Immune SA
Via GlobeNewswire
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases
From AC Immune SA
Via GlobeNewswire
Why Shares of AC Immune Jumped This Week
Via The Motley Fool
Why AC Immune Stock Skyrocketed Today
Via Benzinga
AC Immune Raises $50M, Its Alzheimer's Targeting Immunotherapy Advances Into Phase 2b Trial
Via Benzinga
AC Immune Announces Pricing of Underwritten Offering of Common Shares
From AC Immune SA
Via GlobeNewswire
AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial
From AC Immune SA
Via GlobeNewswire
AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO
From AC Immune SA
Via GlobeNewswire
Penny Stock Powerhouses: 7 Picks Poised for Explosive Growth
Via InvestorPlace
Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others
Via Benzinga
AC Immune to Present at the Jefferies 2023 London Healthcare Conference
From AC Immune SA
Via GlobeNewswire
AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
From AC Immune SA
Via GlobeNewswire
AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer’s Disease as a Surrogate of Clinical Efficacy on November 9, 2023
From AC Immune SA
Via GlobeNewswire
AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic
From AC Immune SA
Via GlobeNewswire
AC Immune Announces Upcoming Presentations at the 16th CTAD Conference
From AC Immune SA
Via GlobeNewswire
AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023
From AC Immune SA
Via GlobeNewswire
AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023
From AC Immune SA
Via GlobeNewswire
AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
From AC Immune SA
Via GlobeNewswire
AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023
From AC Immune SA
Via GlobeNewswire
AC Immune SA Appoints New Chief Medical Officer
From AC Immune SA
Via GlobeNewswire
AC Immune Showcasing Precision Medicine Programs at AAIC 2023
From AC Immune SA
Via GlobeNewswire
Why Walgreens Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.